Daa Pangenotypic Mavyret denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for daa pangenotypic mavyret are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Mavyret as Non-Formulary

UnitedHealthcare's (UHC) commercial formularies tier hepatitis C direct-acting antivirals (DAAs) based on contracted pricing and preferred-drug agreements that shift from plan year to plan year. Mavyret (glecaprevir/pibrentasvir) may be placed on a non-preferred tier or excluded from a specific plan's formulary when a competing pangenotypic DAA holds the preferred position. The non-formulary denial reflects a benefit-design decision, not a clinical determination that Mavyret is inappropriate for your case.

## Why This Denial Is Appealable

Federal and state law require plans to maintain a formulary exception process. When a prescriber documents that the plan-preferred DAA alternative is clinically unsuitable — due to factors such as renal function, drug interactions, prior treatment history, or other patient-specific considerations described in the FDA-approved prescribing labels — UHC must consider an exception request. Non-formulary denials tied to a clinically unsuitable preferred alternative are regularly reversed at both internal and external review.

## Federal Appeal Framework

• ACA §2719 / ERISA §503: Non-formulary denials are subject to full-and-fair internal appeal and independent external review.
• Timeline: Internal appeal must generally be filed within 180 days of the denial notice. External review must generally be requested within 4 months of an internal denial.
• Expedited option: If delay would seriously jeopardize your health, request expedited review; decisions typically required within 72 hours.

## The Appeal Process

1. Confirm which UHC-preferred DAA is on your plan's formulary and obtain the FDA-approved prescribing labels for both that drug and Mavyret. 2. Have your prescriber document why the preferred formulary alternative is clinically unsuitable for this specific patient, citing the relevant labeling differences. 3. Submit a formulary exception request to UHC along with the internal appeal — these can run concurrently. 4. Request a peer-to-peer review between your prescriber and UHC's medical director to discuss the clinical rationale directly. 5. If the exception and internal appeal are both denied, escalate to independent external review.

## Documentation to Gather

• HCV genotype and diagnosis confirmation: Lab results confirming active infection and genotype.
• Clinical rationale for Mavyret: Prescriber letter explaining why the preferred formulary alternative cannot be used for this patient — citing the FDA prescribing label for both drugs and the applicable professional society guidance (e.g., AASLD/IDSA HCV guidance) as the relevant guideline organization.
• Renal function, co-medications, and comorbidities: Chart documentation of any factors that make the preferred alternative inappropriate, per labeling.
• Prior DAA history: Documentation of any prior HCV therapy, including outcomes and reasons for discontinuation, if relevant to formulary exception grounds.

## Criteria-Mapping Structure

Build a two-column table: left column lists each criterion in UHC's formulary exception policy; right column maps each to the specific chart fact, date, and document that satisfies it. The most critical criterion is typically "the formulary alternative is clinically inappropriate" — focus your prescriber letter and chart documentation squarely on that pivot point.